Men facing joint replacement surgery may need to consider their hormone status as a critical risk factor. Low testosterone appears to significantly compromise recovery outcomes, particularly increasing the likelihood of dangerous blood clots that can prove life-threatening. This finding challenges the common practice of overlooking hormonal health in surgical planning and suggests untreated testosterone deficiency creates measurable surgical vulnerabilities.
Analyzing over 133,000 male patients undergoing hip and knee replacements, researchers identified men with testosterone levels below 300 ng/dL as having substantially elevated risks of deep vein thrombosis and pulmonary embolism at 90 days, one year, and two years post-surgery compared to men with normal testosterone levels. The study excluded patients receiving testosterone replacement therapy, focusing specifically on the impact of untreated deficiency. Using propensity score matching to control for age, comorbidities, and other variables, the data revealed consistent patterns of increased thromboembolic complications among testosterone-deficient men.
This represents the first large-scale examination of testosterone's role in joint replacement outcomes, addressing a significant gap given that testosterone deficiency affects roughly 40% of men over 45 yet remains widely undiagnosed and untreated. The mechanism likely involves testosterone's influence on blood coagulation factors and endothelial function. However, the observational nature prevents establishing causation, and the study doesn't address whether pre-surgical testosterone optimization might mitigate risks. For orthopedic surgeons, these findings suggest routine testosterone screening could become a valuable component of pre-operative risk assessment, potentially identifying patients requiring enhanced anticoagulation protocols or hormonal intervention before elective procedures.